Guardant Health Inc. (GH) saw its stock soar 5.68% in after-hours trading on Thursday, following the release of its first-quarter 2026 financial results.
The precision oncology company reported quarterly adjusted losses of $0.45 per share, significantly beating the analyst consensus estimate of $0.76 per share. Revenue for the quarter came in at $301.7 million, surpassing estimates of $279.2 million and representing a 48% increase from the same period last year.
Furthermore, Guardant Health raised its full-year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, up from its previous forecast and above analyst expectations. The strong performance was driven by a 47% increase in oncology test volume and growth in its Shield screening business.
Comments